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Serum CA 125 concentrations in women with
endometriosis or uterine fibroids treated with
gonadotrophin-releasing hormone agonist analogues
z. M. VAN DER SPUY, M. WOOD, G. FIEGGEN, M. SALIE HENDRICKS
Abstract We assessed the possible role of CA 125 in the
Inonitoring of gonadotrophin-releasing hOrInone
(GnRH) agonist analogue therapy in women with
endoInetriosis and uterine fibroids. Serum con-
centrations of this cell surface antigen did not cor-
relate with uterine volume and appeared to have
no value in the asseSSInent of shrinkage of uterine
fibroids during GnRH agonist treatInent. While
CA 125 levels were not always elevated in subjects
with endoInetriosis, they fell during treatInent in
all patients. The change accurately reflected
therapeutic progress in these WOInen and was of
particular value in those patients who had COIn-
menced therapy with elevated levels. It is sug-
gested that CA 125 tnay be useful in the monitor-
ing of therapeutic progress in selected patients
with endoInetriosis treated with GnRH agonists;
the need for surgical follow-up may be obviated.
S AIr MedJ 1993; 83: 510-513.
C A 125 is a cell surface antigen, associated with ahigh-molecular-weight glycoprotein, which isrecognised by the murine monoc1onal antibody,
OC 125. Bast er alY first described the radio-immuno-
assay and demonstrated elevated levels of CA 125 (> 35
U/m!) in the sera of82% of 101 women with non-muci-
nous epithelial carcinoma of the ovary and 1% of an
apparently healthy group of 888 blood donors. Elevated
levels of CA 125 have since been described in a number
of malignant and benign diseases as well as certain phys-
iological conditions such as menstruation and early
pregnancy!
Several studies have noted significant elevation of
CA 125 levels in women with endometriosis, uterine
fibroids and other benign gynaecological conditions and
suggested that this antigen may be of value, both in the
diagnosis of the disease and the monitoring of therapyY
The availability of a marker of disease which could be
used to monitor therapeutic progress is of considerable
value, since it might avoid expensive and invasive fol-
low-up investigations. We treated women who had
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proven endometriosis or uterine fibroids with gonado-
trophin-releasing hormone (GnRH) agonist analogues
and anempted to determine the value of CA 125 in their




Eight women with confirmed endometriosis were
treated with a GnRH agonist analogue (DTrp6, Pro· N-
ethylamide LHRH) in a daily dose of 200 Jlg.
Treatment was initiated during the follicular phase of
the cycle. Blood was taken for the measurement of
serum CA 125 concentrations before the commence-
ment of therapy, after 8 - 12 weeks' treatment and
before surgery at the conclusion of treatment (16 - 24
weeks). Seven of the 8 women had objective reassess-
ment of their endometriotic deposits; the 8th declined
further surgery and was reassessed symptomatically.
Uterine fibroids
Eleven women with fibroids were treated with a long-
acting analogue, 3,6 mg Zoladex (D-Ser (Eu')6 AzglylO-
UIRH; ICI Pharmaceuticals), administered as a depot
implant at 4-week1y intervals for 20 - 24 weeks.
Treatment was started in the follicular phase of the cycle
and myomectomy was performed within 4 weeks of the
last implant. Blood was taken for CA 125 measurements
at the commencement of therapy, after 12 and 20 weeks
of treatment and 8 weeks after the last depot injection
(6 - 8 weeks after myomectomy). Uterine volume was
determined by means of ultrasound on each of these
occasions.
Control subjects
Ten healthy volunteers with normal ovulatory cycles
had serum CA 125 levels determined on day 6 of the
cycle. These measurements served as normal control
values for this study.
CA 125 assay
CA 125 was measured by means of a simultaneous
sandwich solid-phase radio-immunoassay with a com-
mercial kit (Abbon CA 125 RIA, Abbon Laboratories
Diagnostic Division, North Chicago, Ill.). The sensiti-
vity of the assay was 5 U/m! and the intra-assay coeffi-
cient of variation was 10%. All samples described here
were measured in a sirIgle assay.
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Statistics
Analysis of variance was used to determine differences
between groups in CA 125 levels. Where necessary,
because of the non-homogeneity of variance, a log trans-






Consent to perform these studies was obtained from the
Ethics and Research Committee of the University of


















clinically. The CA 125 levels subsequently reached a
plateau suggesting therapeutic non-compliance, there
was a rise in oestradiol concentrations and a relapse in
her condition. She complained of abdominal and chest
pain during menses and on examination, was found to
have a right-sided haemothorax. Thoracotomy was per-
formed and the tentative diagnosis of a pleural
endometrioma was made - although the histological
findings were not conclusive. GnRH agonist therapy
was recommenced and CA 125 levels fell to 13,1 D/ml.
At repeat laparotomy (to repair an incisional hernia) she
was found to be free of active endometriosis.
ThroughOut her treatment, the CA 125 concentrations
accurately mirrored the endometriotic activity.
FIG. 1.
Serum concentrations of CA 125 in healthy women,
women with endometriosis and women with uterine
fibroids. The horizontal line indicates1he mean of the
values in each group. All samples were taken in the folli-
cular phase of the ovarian cycle before therapy started.
Although the mean value and the range of CA 125 levels
were significantly higher in the women with endometrio-
sis, there was considerable overlap in the three groups.
Four of the subjects with endometriosis and 2 of the
















CA 125 concentrations at the initiation
of therapy
The serum concentrations of CA 125 in the control sub-
jects and the two groups of patients are shown in Fig. 1.
There was a significant difference in the initial levels of
CA 125 in the 3 groups CP2,26 =4,338; P< 0,025).
The mean concentration (± SEM) of CA 125 in the
patients with endometriosis was 65,9 ± 24,7 U/m! with
a range of 8,3 - 200,9 Ulm!. This was significantly high-
er than the levels found in the control subjects which
ranged from 5,8 to 38,3 U/m! (f,,26 =6,178; P < 0,025).
In contrast, in the women with uterine fibroids, the
initial CA 125 concentrations were not significantly
different from those of the controls and ranged from 3,5
to 45,8 U/m! with a mean (± SEM) of 19,2 ± 4,3 Ulm!.
Although the mean value and the range of CA 125 were
significantly higher in the women with endometriosis,
there was considerable overlap in the three groups
(Fig. 1).
CA 125 concentrations during therapy in
endometriosis patients
All 8 patients with endometriosis demonstrated clinical
improvement during treatment. Serum oestradiol con-
centrations fell to < 200 pmol/l within 3 weeks of com-
mencing agonist treatment and were maintained at this
level throughout therapy. Six of the women underwent
tubal surgery at the conclusion of therapy and at laparo-
tomy there was no evidence of active endometriosis.
One woman had an umbilical endometrioma which
regressed during treatment; she has subsequently
remained asymptomatic. The remaining patient stopped
therapy after 6 months and remains symptom-free 2
years later.
In Fig. 2 the changes in CA 125 concentrations dur-
ing treatment are illustrated. CA 125 concentrations fell
in all patients. The mean concentration pre-treatment
(65,9 ± 24,7 U/m!) fell to 12,3 ± 4,7 D/m! after 8 - 12
weeks and finally reached a level of 6,9 ± 1,24 U/m! at
the conclusion of therapy CPZ,ZI = 15,855; P < 0,001).
There was a significant change between the initial
measurements and those taken after 8 - 12 weeks' treat-
ment (Fp, = 24,735; P < 0,001) and at the end of
therapy eFl,21 = 22,791; P < 0,001). However, .the fall
between 8 - 12 weeks and the end of treatment was not
significant, suggesting that the maximal therapeutic
benefit was achieved in the first 3 months of the induced
hypo-oestrogen state.
In Fig. 3 the changes in CA 125 concentrations in
one of the patients with severe endometriosis are noted.
This woman presented with ascites and a pelvic mass,
and at exploratory laparotomy, severe endometriosis was
diagnosed and histologically confirmed. Initial CA 125
levels were 137,1 U/ml when treatment with GnRH
agonist was instituted. CA 125 concentrations fell dur-












CA 125 concentrations in women with
uterine fibroids
All 11 women treated with GnRH agonist analogue
demonstrated a decrease in urerine and fibroid volume
after 8 - 12 weeks of therapy. The urerine volumes and
CA 125 levels pre- and post-therapy are given in Table
1. There was no correlation between the volume of the
uteri and CA 125 concentrations either pre-treatmenr or
post-therapy and myomecromy er = 0,364; T = 1,173;
df = 9; P = 0,271 v. r = 0,576; T = 2,117; df = 9; P =
0,063). The CA 125 concentrations are illustrated in
Fig. 4 and did not change significantly during therapy
















PRE-THERAPY 8-12 WEEKS CONCLUSION
THERAPY OF THERAPY
FIG. 2.
Changes in CA 125 levels during GnRH agonist therapy in
8 women with endometriosis. The horizontal bar shows
the mean concentrations pre-treatment, after 8 - 12 weeks
and at the end of therapy. There is a significant fall after


























Response to GnRH agonist therapy in a patient with
endometriosis. Her clinical course is described in the text.
The times of surgical intervention are indicated by the
arrows and the serum CA 125 levels accurately reflect her


















CA 125 concentrations in 11 women with uterine fibroids.
Serum concentrations of CA 125 before therapy, after 12
and 24 weeks and after myomectomy and the recovery of
the hypothalamic-pituitary-ovarian axis from GnRH ago-
nist suppression are shown. The horizontal bar indicates
the mean concentration at each of the times noted. Only 2
subjects had values outside the normal range before
therapy and-these values were not markedly elevated.
Discussion
This srudy has assessed the value of CA 125 as a marker
of clinical progress in the treatmenr of endometriosis
and uterine fibroids with GnRH agonist analogues.
These peptides induce a state of 'medical castration'
and the subsequent hypo-oestrogenism will cause
regression of oestrogen-dependent conditions such as
endometriosis and uterine fibroids.
It has been suggested that CA 125 is a marker of
uterine fibroids and might be used ro assess progress of
patients treated with GnRH agonists. 6 However, in the
patienrs presenred here who were treated with GnRH
agonists before myomectomy, CA 125 did not correlate
with the size of the fibroids, the uterine volume or the
response ro therapy. The shrinkage of fibroids with
GnRH agonist is best monitored by means of ultra-
sound, which has the added advantage of being able to
describe the number, position and size of the fibroids.
The small non-significant fall in CA 125 values which




Uterine volumes and CA 125 concentrations in women with fibroids treated with GnRH agonist analogues
Before commencing GnRH Post-GnRH agonist therapy
agonist therapy 6- 8 weeks after myomectomy
Patient No. Volume (mI) CA 125 (U/ml) Volume (mI) CA 125 (U/ml)
1 1 774 26,4 454 16,4
2 516 27,0 282 29,6
3 710 7,0 162 6,5
4 482 3,5 45 3,9
5 684 16,6 47 9,1
6 734 5,3 114 4,0
7 769 15,2 95 7,6
8 223 8,1 79 7,2
9 274 15,3 88 16,5
10 1061 40,8 180 23,2
11 636 45,8 86 8,6
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probably the consequence of suppression of derivates of
coelomic epithelium by the induction of a hypo-
oestrogen state.
Four of the 8 women with endometriosis had elevat-
ed pre-treatment levels of CA 125. All 8 patients
demonstrated a fall of CA 125 during therapy with
GnRH agonist and normal levels were achieved after
only 8 - 12 weeks of treatment. At re-assessment of 7
patients during surgery no evidence of active endo-
metriosis was found. The patient whose clinical course
is described in Fig. 3 was temporarily non-compliant
and her retarded clinical progress was illustrated by the
CA 125 plateau; normal levels were only achieved once
effective therapy was re-instituted.
In this study CA 125 levels correctly reflected the
clinical improvement in the 4 women who initially had
elevated levels while in the remaining patients CA 125
was reduced by 50% following GnRH agonist treat-
ment. In contrast, CA 125 has been reported to be of
limited value in the assessment of clinical progress dur-
ing the treatment of endometriosis with danazol or
medroxyprogesterone acetate and may even rise after
progesterone administration. 8
Since endometriotic lesions are of embryonic coelo-
mic epithelial origin, CA 125 is likely to be a marker of
endometriosis. If the endometriotic tissue sheds this
antigen, the detection thereof in peripheral serum is
limited by the blood supply or the presence of fibrosis
surrounding endometriotic deposits. CA 125 has a Iow
specificity and elevated levels have also been reported in
women with malignant ovarian rumours, pelvic inflam-
matory disease, endometriosis and other benign and
malignant disease.",·,5 While CA 125 appears helpful in .
the follow-up of advanced ovarian malignant disease
and the detection of recurrence, it is of limited value in
the early diagnosis of, or as a screening test for epithelial
carcinomas, since a minimum rumour load is required
before CA 125 levels are elevated"·ll
With 35 DIm! as the upper limit of normal, elevated
levels of CA 125 were reported by Barbieri er al." in
54% of women with stage ill or IV endometriosis, 14%
of women \\rith fibroids and 13% ofwomen with stage IT
endometriosis. Similar results have been reported by
other authors, but the Iow sensitivity of the measure-
ment of CA 125 in endometriosis makes it an unsuit-
able screening test for this conditionY'
The patient with endometriosis, however, is often
subjected to repeated laparoscopic examination of the
pelvis to assess progress during and after therapy or to
determine whether recurrence of disease has occurred.
We suggest that CA 125 is a valuable adjuvant in the
management of endometriosis when it is treated with
GnRH agonist analogues. Surgical intervention may be
avoided and medical therapy adjusted according to the
CA 125 levels and relapse or remission may be diag-
nosed in seleCted patients. The initial assessment of
women with suspected endometriosis should include
laparoscopy and biopsy and the measurement of CA
125. In those patients who have elevated levels, CA 125
may be used to monitor progress when GnRH agonist
treatment is used, although its value with other forms of
therapy is limited. Once these levels have been nor-
malised, definitive surgery or cessation of therapy may
be contemplated and CA 125 levels may be used for
future follow-up.
While CA 125 is apparently of no clinical value in
the monitoring of the response of fibroids to GnRH
agonist treatment, it certainly has a role in the manage-
ment of endometriosis. Repeated measurements of CA
125 in selected patients with endometriosis, in conjunc-
tion with clinical assessment, would be both cost-effec-
tive and less invasive than repeated surgical procedures.
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